Cargando…

B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis

In melanoma, the RAS/RAF/MEK/ERK signalling pathway is an area of great interest, because it regulates tumor cell proliferation and survival. A varying mutation rate has been reported for B-RAF and N-RAS, which has been largely attributed to the differential source of tumor DNA analyzed, e.g., fixed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ugurel, Selma, Thirumaran, Ranjit K., Bloethner, Sandra, Gast, Andreas, Sucker, Antje, Mueller-Berghaus, Jan, Rittgen, Werner, Hemminki, Kari, Becker, Jürgen C., Kumar, Rajiv, Schadendorf, Dirk
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1794595/ https://www.ncbi.nlm.nih.gov/pubmed/17311103 http://dx.doi.org/10.1371/journal.pone.0000236

Ejemplares similares

STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFNα Therapy in Stage III Melanoma Patients
por: Schrama, David, et al.
Publicado: (2014)

Association of Inherited Variation in Toll-Like Receptor Genes with Malignant Melanoma Susceptibility and Survival
por: Gast, Andreas, et al.
Publicado: (2011)

Lack of clinical efficacy of imatinib in metastatic melanoma
por: Ugurel, S, et al.
Publicado: (2005)

Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations
por: Cosgarea, Ioana, et al.
Publicado: (2017)

Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL fusion transcripts
por: Xie, Huaping, et al.
Publicado: (2016)

SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma
por: Willmes, Christoph, et al.
Publicado: (2016)

RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
por: Jin, Ting, et al.
Publicado: (2017)

BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
por: Peiffer, Lukas, et al.
Publicado: (2020)

Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?
por: Bouwhuis, Marna G., et al.
Publicado: (2009)

Influence of Genetic Variants in Type I Interferon Genes on Melanoma Survival and Therapy
por: Lenci, Romina Elizabeth, et al.
Publicado: (2012)

Ras and Raf pathways in epidermis development and carcinogenesis
por: Kern, F, et al.
Publicado: (2011)

Ras and Raf pathways in epidermis development and carcinogenesis
por: Kern, F, et al.
Publicado: (2011)

KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation
por: Tran, Timothy H., et al.
Publicado: (2021)

Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies
por: Utikal, Jochen, et al.
Publicado: (2007)

Molecular recognition of RAS/RAF complex at the membrane: Role of RAF cysteine-rich domain
por: Travers, Timothy, et al.
Publicado: (2018)

Crystal Structure Reveals the Full Ras–Raf Interface and Advances Mechanistic Understanding of Raf Activation
por: Cookis, Trinity, et al.
Publicado: (2021)

Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS
por: Ilter, Metehan, et al.
Publicado: (2022)

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis
por: Houben, Roland, et al.
Publicado: (2004)

An engineered protein antagonist of K-Ras/B-Raf interaction
por: Kauke, Monique J., et al.
Publicado: (2017)

Does Ras Activate Raf and PI3K Allosterically?
por: Nussinov, Ruth, et al.
Publicado: (2019)

Cryo-EM structure of a RAS/RAF recruitment complex
por: Park, Eunyoung, et al.
Publicado: (2023)

Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma
por: Wong, Kwan Yeung, et al.
Publicado: (2018)

Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis
por: Fritsche-Guenther, Raphaela, et al.
Publicado: (2016)

Role of autophagy in K-RAS- and B-RAF-driven lung cancers
por: White, Eileen
Publicado: (2014)

T cell leukemia control via Ras-Raf pathway inhibition with peptides
por: Marin, G, et al.
Publicado: (2017)

Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer
por: Gonzalez-Hormazabal, Patricio, et al.
Publicado: (2018)

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
por: Degirmenci, Ufuk, et al.
Publicado: (2020)

Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling
por: Nolan, Aoife A., et al.
Publicado: (2021)

Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity
por: Thier, Beatrice, et al.
Publicado: (2022)

Correction to: T cell leukemia control via Ras-Raf pathway inhibition with peptides
por: Marin, GH, et al.
Publicado: (2018)

Reusability and composability in process description maps: RAS–RAF–MEK–ERK signalling
por: Mazein, Alexander, et al.
Publicado: (2021)

Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors
por: Lai, Lick Pui, et al.
Publicado: (2022)

Impact of RAS/RAF mutations on clinical and prognostic outcomes in metastatic colorectal cancer
por: Dolatkhah, Roya, et al.
Publicado: (2021)

Publisher Correction: Cryo-EM structure of a RAS/RAF recruitment complex
por: Park, Eunyoung, et al.
Publicado: (2023)

Harmine suppresses hyper-activated Ras–MAPK pathway by selectively targeting oncogenic mutated Ras/Raf in Caenorhabditis elegans
por: Ji, Jiaojiao, et al.
Publicado: (2019)

Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotype
por: Albrecht, Lea Jessica, et al.
Publicado: (2022)

Primary staging and follow-up in melanoma patients – monocenter evaluation of methods, costs and patient survival
por: Hofmann, U, et al.
Publicado: (2002)

Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A(3) adenosine receptor
por: Merighi, Stefania, et al.
Publicado: (2006)

Galectin-1 dimers can scaffold Raf-effectors to increase H-ras nanoclustering
por: Blaževitš, Olga, et al.
Publicado: (2016)

The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
por: Li, Lei, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vsc7da2h04ve6rk1u75itifdf0